HP for Mad Lab Siena
21 images Created 30 Oct 2020
Monoclonal Antibody Discovery (MAD) Lab di Fondazione Toscana Life Sciences , tuscany
The MAD Lab research team at TLS Foundation started activities in 2018 thanks to a 2.5 million euros ERC Advanced Grant focused on anti-microbial resistance and has grown quickly thanks to various funding sources received for tackling different health challenges (Shigella, Klebsiella pneumoniae and, more recently, coronavirus SARS-CoV-2). The Lab has consolidated skills in the identification and production of monoclonal antibodies that can be tested in vitro against bacteria and viruses.
MabCo19 Project, started in collaboration with INMI Spallanzani, is focused on the discovery and development of human monoclonal antibodies against coronavirus SARS-CoV-2, from blood of recovering/recovered patients, with the aim of using them for prophylactic/therapeutic purposes and as molecular baits for the discovery of vaccine antigens. The experimental approach followed is called Reverse Vaccinology 2.0, which represents the evolution of the first Reverse Vaccinology strategy optimized by Dr. Rino Rappuoli.
The MAD Lab research team at TLS Foundation started activities in 2018 thanks to a 2.5 million euros ERC Advanced Grant focused on anti-microbial resistance and has grown quickly thanks to various funding sources received for tackling different health challenges (Shigella, Klebsiella pneumoniae and, more recently, coronavirus SARS-CoV-2). The Lab has consolidated skills in the identification and production of monoclonal antibodies that can be tested in vitro against bacteria and viruses.
MabCo19 Project, started in collaboration with INMI Spallanzani, is focused on the discovery and development of human monoclonal antibodies against coronavirus SARS-CoV-2, from blood of recovering/recovered patients, with the aim of using them for prophylactic/therapeutic purposes and as molecular baits for the discovery of vaccine antigens. The experimental approach followed is called Reverse Vaccinology 2.0, which represents the evolution of the first Reverse Vaccinology strategy optimized by Dr. Rino Rappuoli.
